Medically Reproducing Bariatric Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-31

Study Completion Date

2018-10-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Type 2 diabetes (DM2) is a chronic disease affecting 29 million Americans and a leading cause of blindness, kidney failure, and limb loss (Engelgau et al 2004). Roux-en-Y gastric bypass (RYGB) is the only intervention that leads to durable DM2 remission \~ 80% of the time (Mingrone et al 2012). Yet, it's broad application is limited by cost, invasiveness, and clinical inertia. Medically reproducing RYGB would extend the benefit of disease remission to the vast majority of DM2 patients using a cheaper, less invasive and more palatable treatment approach. Although all of the mechanisms mediating DM2 remission are not known, it is widely accepted that RYGB induces caloric restriction and enhances meal-stimulated release of a gut-peptide called glucagon-like-peptide-1 (GLP-1) both of which improve glycemic control in type 2 diabetes (Dar et al 2012; Jackness 2013). Caloric restriction can be achieved using OPTIFAST which is a commercially available medical weight loss program that has demonstrated the ability to decrease weight and improve glycemic control (Kirschner et al; 1998). Enhanced meal-stimulated GLP-1 release can be achieved using Liraglutide an FDA-approved once daily GLP-1 analogue that improves glycemic control and induces weight loss.

The investigators hypothesize that adding OPTIFAST (caloric restriction) in suboptimally controlled DM2 patients on Liraglutide (enhanced meal stimulated GLP-1 release), Metformin and Lantus insulin will medically reproduce RYGB and lead to DM2 remission, weight loss, decreased medication intensity and improved health related quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanisms Behind Antidiabetic Effects by Gastric By-pass

NCT01708096

Diabetes Mellitus Typ 2 and Obesity

COMPLETED NA

Effect of Gastric Bypass on Patients With Type 2 Diabetes and/or Dyslipidemia

NCT00879125

Type 2 Diabetes

COMPLETED

Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans

NCT02710370

Obesity Diabetes Mellitus, Type 2 Endocrine System Diseases +2 more

ACTIVE_NOT_RECRUITING

Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus

NCT01083108

Obesity Bariatric Surgery Morbid Obesity +2 more

TERMINATED PHASE2

Mechanisms of Diabetes Control After Weight Loss Surgery

NCT00571220

Gastric Bypass Surgery Obesity

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 24 week "proof of concept" study that will examine if adding "caloric restriction" (OPTIFAST) to "enhanced GLP-1 release" (Liraglutide) will lead to discontinuation of Lantus and Metformin. The primary outcome measure is change in glycemic control measured as hemoglobin A1C. Secondary outcome measures are change in weight, medication intensity and health related quality of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

"Proof of concept" study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OPTIFAST

Subjects meeting inclusion criteria will be receive OPTIFAST meal replacement (MR) in the following manner:

WK1-WK12 (5 MR/DAY)

WK13-14 (4 MR/DAY)

WK 15 (3 MR/DAY)

WK 16 (2 MR/DAY)

WK 17-18 (1 MR/DAY)

WK 19-24 (No MR)

Group Type EXPERIMENTAL

OPTIFAST

Intervention Type OTHER

OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OPTIFAST

OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male or female
* age 25-70 years
* BMI \> 30
* diagnosis of type 2 diabetes
* weight stable for 3 months
* hemoglobin A1C \>7% and \<10%
* on Liraglutide
* on Metformin
* on Lantus
* interested in losing weight
* agreeable to regular visits per study protocol
* access to telephone and reliable transportation
* has a VAMC provider

Exclusion Criteria

* age \>70
* A1C \<7% or \>10%
* current use of prandial insulin
* current use of sulfonylurea or any other oral agent except for Metformin
* current sue of any other basal insulin except for Lantus
* pregnant
* breast feeding
* prior history of pancreatitis
* prior history of gastroparesis
* history of thyroid cancer/multiple endocrine neoplasia/thyroid nodules/medullary thyroid cancer
* history of gallstones
* history of hyperoxaluria or calcium oxalate nephrolithiasis
* AST/ALT \> 2 times the upper limit of normal
* current or past history of liver disease
* history of Roux-en-Y gastric bypass or gastric sleeve or any other bariatric procedure
* type 1 diabetes
* any gastrointestinal disease causing malabsorption
* unwilling or unable to complete scheduled testing
* thiazolidinedione use within past 6 months
* any serious and/or unstable medical, psychiatric, or other condition(s) that prevents the patient from providing informed consent or complying with the study
* organ transplantation or those on immunosuppressants
* chronic anticoagulation
* recent myocardial infarction, unstable angina, stroke, coronary artery bypass or transient ischemia attacks in the past 6 months
* chronic prednisone use
* peptic ulcer disease in past 6 months
* acute gastrointestinal disorders
* hepatitis
* cirrhosis
* GFR \< 50
* deep vein thrombosis in the past 6 months
* bone fractures in the past 6 months
* lithium use
* active malignancy
* substance abuse
* unstable psychiatric condition
* history of suicidal ideation
* enrolled in another research study related to diet and/or physical activity

Minimum Eligible Age

25 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No